Survey for Government Policies Regarding Strategies for the Commercialization and Globalization of Digital Therapeutics
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: This study was conducted to build a direction for government policies regarding strategies for the commercialization of digital therapeutics in Korea, as well as its globalization. Materials and Methods: The study included 37 participants from the Korea Digital Health Industry Association (KODHIA). The data was based on a survey conducted in 2020 targeting employees of companies engaged in the digital health industry in Korea. Participants were asked about their involvement in product development of digital therapeutics and their opinion about the growing motivator for digital therapeutics in Korea and the global market. Results: According to our data, among subjects not involved in making digital therapeutics products, the main reason for not being involved was the lack of experts (73.9%) and difficulty in licensing (73.9%). Responses concerning the priority area in need of national support were R&D funding (43.2%), and the next was licensing guidance and simplifying regulations (24.3%). Possible difficulties of overseas market expansion were the unfamiliarity in digital therapeutics technology verification and licensing structures of foreign countries (73%), and concerns regarding the level of recognition of clinical trials and technology in Korea from overseas (70.3%). Overall, respondents were hesitant in starting a related business due to the lack of government support and the complexity of the regulation process. Moreover, concerns about global market entry were similar. Being unfamiliar with the novel process and worrying about the achievement despite existing challenges were the biggest drawback. Conclusion: For the digital therapeutics industry to evolve domestically and internationally, government support and guidance are essential.
Abstract
Purpose: This study was conducted to build a direction for government policies regarding strategies for the commercialization of digital therapeutics in Korea, as well as its globalization. Materials and Methods: The study included 37 participants from the Korea Digital Health Industry Association (KODHIA). The data was based on a survey conducted in 2020 targeting employees of companies engaged in the digital health industry in Korea. Participants were asked about their involvement in product development of digital therapeutics and their opinion about the growing motivator for digital therapeutics in Korea and the global market. Results: According to our data, among subjects not involved in making digital therapeutics products, the main reason for not being involved was the lack of experts (73.9%) and difficulty in licensing (73.9%). Responses concerning the priority area in need of national support were R&D funding (43.2%), and the next was licensing guidance and simplifying regulations (24.3%). Possible difficulties of overseas market expansion were the unfamiliarity in digital therapeutics technology verification and licensing structures of foreign countries (73%), and concerns regarding the level of recognition of clinical trials and technology in Korea from overseas (70.3%). Overall, respondents were hesitant in starting a related business due to the lack of government support and the complexity of the regulation process. Moreover, concerns about global market entry were similar. Being unfamiliar with the novel process and worrying about the achievement despite existing challenges were the biggest drawback. Conclusion: For the digital therapeutics industry to evolve domestically and internationally, government support and guidance are essential.
참고문헌 (23)
- Patel NA, "Characteristics and challenges of the clinical pipeline of digital therapeutics", NPJ Digit Med, 3, pp.159~ (2020)
- Chul-Hyun Cho, "Could Digital Therapeutics be a Game Changer in Psychiatry?", PSYCHIATRY INVESTIGATION, 16(2), pp.97~98 (2019), 대한신경정신의학회[DOI]
- Adler-Milstein J, "From digitization to digital transformation : policy priorities for closing the gap", JAMA, 325, pp.717~718 (2021)
- Sverdlov O, "Digital therapeutics : an integral component of digital innovation in drug development", Clin Pharmacol Ther, 104, pp.72~80 (2018)
- Rosa C, "Using e-technologies in clinical trials", Contemp Clin Trials, 45, pp.41~54 (2015)
- Ellis TD, "Digital therapeutics in Parkinson’s disease : practical applications and future potential", J Parkinsons Dis, 11, pp.S95~S101 (2021)
- Thomas E, "Future-proofing cardiac rehabilitation : transitioning services to telehealth during COVID-19", Eur J Prev Cardiol, 28, pp.e35~e36 (2021)[DOI]
- Kim Hun-Sung, "Towards Telemedicine Adoption in Korea: 10 Practical Recommendations for Physicians", Journal of Korean Medical Science, 36(17), pp.1~9 (2021), 대한의학회[DOI]
- Han S, "Global healthcare industry trend. Global ICT Issue" (2019), Startup Support Team, National IT Industry Promotion Agency (NIPA)
- Suh KH, "The latest global trends in digital health", Medical Policy Forum, pp.1~34 (2020), Research Institute for Healthcare Policy
- Lougheed T, "How"digital therapeutics"differ from traditional health and wellness apps", CMAJ, 191, pp.E1200~E1201 (2019)
- Inan OT, "Digitizing clinical trials", NPJ Digit Med, 3, pp.101~ (2020)
- Esser M, "PNS100 the new reimbursement route for digital health applications(DIGA)in Germany : critical appraisal and first evaluation of the possible effect on the German healthcare system", Value Health, 23, pp.S658~S659 (2020)
- Gerke S, "Germany’s digital health reforms in the COVID-19 era : lessons and opportunities for other countries", NPJ Digit Med, 3, pp.94~ (2020)
- Asthana S, "Why does the NHS struggle to adopt eHealth innovations? A review of macro, meso and micro factors", BMC Health Serv Res, 19, pp.984~ (2019)
- Kadakia K, "Advancing digital health : FDA innovation during COVID-19", NPJ Digit Med, 3, pp.161~ (2020)
- Campbell AN, "Internet-delivered treatment for substance abuse : a multisite randomized controlled trial", Am J Psychiatry, 171, pp.683~690 (2014)
- Christensen DR, "Adding an internet-delivered treatment to an efficacious treatment package for opioid dependence", J Consult Clin Psychol, 82, pp.964~972 (2014)
- McGregor BA, "Remote oncology care : review of current technology and future directions", Cureus, 12, pp.e10156~ (2020)
- Anguera JA, "Video game training enhances cognitive control in older adults", Nature, 501, pp.97~101 (2013)
- Morin CM, "Profile of Somryst prescription digital therapeutic for chronic insomnia : overview of safety and efficacy", Expert Rev Med Devices, 17, pp.1239~1248 (2020)
- Kollins SH, "A novel digital intervention for actively reducing severity of paediatric ADHD(STARS-ADHD) : a randomised controlled trial", Lancet Digit Health, 2, pp.e168~e178 (2020)
- 김재현, "디지털 치료기술 산업 육성에 따른 투자와 경제적 파급효과", 보건행정학회지, 30(4), pp.438~443 (2020), 한국보건행정학회